No Data
Nektar Therapeutics Up After Leukemia Candidate Found Beneficial in Early-Stage Study
Nektar Announces Publication In Blood Of Phase 1 Data For Novel IL-15 Agonist NKTR-255 In Combination With Autologous CD19-22 CAR-T Cell Therapy In Patients With B-cell Acute Lymphoblastic Leukemia
Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination With Autologous CD19-22 CAR-T Cell Therapy in Patients With B-cell Acute Lymphoblastic Leukemia
Nektar Rises 11% as BTIG Initiates Buy Rating on Autoimmune Disorders Asset
BTIG Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $4
Nektar Therapeutics Analyst Ratings
Qui Vivra Verra : hope this helps people with leukaemia, very promising
Trytosaveabit OP Qui Vivra Verra : You and me both! 🩷